CSL Licenses AML Treatment To Johnson & Johnson Unit
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL and Johnson & Johnson's Janssen Biotechnology have signed an agreement to develop a new way of treating a form of leukemia by drawing on CSL's monoclonal antibody work.